No Evidence for Selection of HIV-1 with Enhanced Gag-Protease or Nef Function among Breakthrough Infections in the CAPRISA 004 Tenofovir Microbicide Trial

PLoS ONE

Volumn 8, Issue 8, 2013, Pages

  Chopera, Denis R ^a,b,c,d   Mann, Jaclyn K ^a   Mwimanzi, Philip ^c   Omarjee, Saleha ^a   Kuang, Xiaomei T ^c   Ndabambi, Nonkululeko ^b   Goodier, Sarah ^b   Martin, Eric ^c,d   Naranbhai, Vivek ^e   Karim, Salim Abdool ^e   Karim, Quarraisha Abdool ^e   Brumme, Zabrina L ^c,d   Ndung'u, Thumbi ^a,f   Williamson, Carolyn ^b   Brockman, Mark A ^c,d  

^a UNIVERSITY OF KWAZULU NATAL   (South Africa)

^b NATIONAL HEALTH LABORATORY SERVICE   (South Africa)

^c SIMON FRASER UNIVERSITY   (Canada)

^d BRITISH COLUMBIA CENTRE FOR EXCELLENCE IN HIV AIDS   (Canada)

^e UNIVERSITY OF KWAZULU NATAL   (South Africa)

^f MAX PLANCK INSTITUTE FOR INFECTION BIOLOGY   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

CD4 ANTIGEN; HLA ANTIGEN; MEMBRANE PROTEIN; NEF PROTEIN; PLACEBO; PROTEINASE; TENOFOVIR;

ARTICLE; CD4 LYMPHOCYTE COUNT; CLINICAL STUDY; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOWN REGULATION; GAG PROTEASE GENE; GEL; GENE AMPLIFICATION; GENE CLUSTER; GENE FUNCTION; GENE ISOLATION; GENE SEQUENCE; GENETIC DIFFERENCE; GENETIC TRANSFECTION; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1 INFECTION; IMMUNOPATHOGENESIS; IN VITRO STUDY; MAJOR CLINICAL STUDY; MOLECULAR CLONING; NEF GENE; NONHUMAN; NUCLEOTIDE SEQUENCE; PHYLOGENY; SEQUENCE ANALYSIS; VIRAL PHENOMENA AND FUNCTIONS; VIRUS FITNESS; VIRUS GENE; VIRUS LOAD; VIRUS RECOMBINANT; VIRUS REPLICATION; VIRUS TRANSMISSION;

ADENINE; ANTI-HIV AGENTS; CLINICAL TRIALS AS TOPIC; FEMALE; GAG GENE PRODUCTS, HUMAN IMMUNODEFICIENCY VIRUS; HIV INFECTIONS; HIV-1; HUMANS; NEF GENE PRODUCTS, HUMAN IMMUNODEFICIENCY VIRUS; ORGANOPHOSPHONATES; PHYLOGENY; SEQUENCE ANALYSIS, DNA; VAGINAL CREAMS, FOAMS, AND JELLIES; VIRUS REPLICATION;

EID: 84883173982     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0071758     Document Type: Article

References (17)

1. Abdool Karim Q, Abdool Karim SS, Frohlich JA, Grobler AC, Baxter C, et al. (2010) Effectiveness and safety of tenofovir gel, an antiretroviral microbicide, for the prevention of HIV infection in women. Science 329: 1168-1174.
2. Valley-Omar Z, Sibeko S, Anderson J, Goodier S, Werner L, et al. (2012) CAPRISA 004 tenofovir microbicide trial: no impact of tenofovir gel on the HIV transmission bottleneck. J Infect Dis 206: 35-40.
3. Rolland M, Edlefsen PT, Larsen BB, Tovanabutra S, Sanders-Buell E, et al. (2012) Increased HIV-1 vaccine efficacy against viruses with genetic signatures in Env V2. Nature 490: 417-420.
4. Brockman MA, Brumme ZL, Brumme CJ, Miura T, Sela J, et al. (2010) Early selection in Gag by protective HLA alleles contributes to reduced HIV-1 replication capacity that may be largely compensated for in chronic infection. J Virol 84: 11937-11949.
5. Brumme ZL, Li C, Miura T, Sela J, Rosato PC, et al. (2011) Reduced replication capacity of NL4-3 recombinant viruses encoding reverse transcriptase-integrase sequences from HIV-1 elite controllers. J Acquir Immune Defic Syndr 56: 100-108.
6. Chopera DR, Woodman Z, Mlisana K, Mlotshwa M, Martin DP, et al. (2008) Transmission of HIV-1 CTL escape variants provides HLA-mismatched recipients with a survival advantage. PLoS Pathog 4: e1000033.
7. Corro G, Rocco CA, De Candia C, Catano G, Turk G, et al. (2012) Genetic and functional analysis of HIV type 1 nef gene derived from long-term nonprogressor children: association of attenuated variants with slow progression to pediatric AIDS. AIDS Res Hum Retroviruses 28: 1617-1626.
8. Miura T, Brumme ZL, Brockman MA, Rosato P, Sela J, et al. (2010) Impaired replication capacity of acute/early viruses in persons who become HIV controllers. J Virol 84: 7581-7591.
9. Mwimanzi P, Markle TJ, Martin E, Ogata Y, Kuang XT, et al. (2013) Attenuation of multiple Nef functions in HIV-1 elite controllers. Retrovirology 10: 1.
10. Wright JK, Brumme ZL, Carlson JM, Heckerman D, Kadie CM, et al. (2010) Gag-protease-mediated replication capacity in HIV-1 subtype C chronic infection: associations with HLA type and clinical parameters. J Virol 84: 10820-10831.
11. Wright JK, Novitsky V, Brockman MA, Brumme ZL, Brumme CJ, et al. (2011) Influence of Gag-protease-mediated replication capacity on disease progression in individuals recently infected with HIV-1 subtype C. J Virol. 85: 3996-4006.
12. Pond SL, Frost SD, Muse SV, (2005) HyPhy: hypothesis testing using phylogenies. Bioinformatics 21: 676-679.
13. Guindon S, Dufayard JF, Lefort V, Anisimova M, Hordijk W, et al. (2010) New algorithms and methods to estimate maximum-likelihood phylogenies: assessing the performance of PhyML 3.0. Syst Biol 59: 307-321.
14. Mwimanzi P, Markle TJ, Ogata Y, Martin E, Tokunaga M, et al. (2013) Dynamic range of Nef functions in chronic HIV-1 infection. Virology 439: 74-80.
15. Mureithi MW, Poole D, Naranbhai V, Reddy S, Mkhwanazi NP, et al. (2012) Preservation HIV-1-specific IFNgamma+ CD4+ T-cell responses in breakthrough infections after exposure to tenofovir gel in the CAPRISA 004 microbicide trial. J Acquir Immune Defic Syndr 60: 124-127.
16. Tobiume M, Takahoko M, Yamada T, Tatsumi M, Iwamoto A, et al. (2002) Inefficient enhancement of viral infectivity and CD4 downregulation by human immunodeficiency virus type 1 Nef from Japanese long-term nonprogressors. J Virol 76: 5959-5965.
17. Zuo J, Suen J, Wong A, Lewis M, Ayub A, et al. (2012) Functional analysis of HIV type 1 Nef gene variants from adolescent and adult survivors of perinatal infection. AIDS Res Hum Retroviruses 28: 486-492.